In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Xueyu Wang *Tuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.ORCID 0009-0006-3684-3861 Shan Gao *Tuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Xia Yu *National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-1400-7321 Yongguo LiShanghai Jiatan Pharmatech Co., Ltd., Shanghai, China.
Lei LiShanghai Jiatan Pharmatech Co., Ltd., Shanghai, China.
Naihui ChuTuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Hairong HuangNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-4295-4262 Wenjuan NieTuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-1109-1983 Funding
Beijing Municipal Health Commission Dengfeng Program G202511062Beijing Municipal Health Commission Excellent Clinical Research Program for Research-Oriented Wards BRWEP2024W042160109Beijing Tongzhou District Science and Technology Program Project WS2024017
6 · The paper itselfAbstract
Indexed as
Anti-Bacterial AgentsClarithromycinClofazimineMycobacterium Infections, NontuberculousAnimalsChromatography, LiquidDrug Therapy, CombinationLungMaleMycobacterium abscessusPyridinesRatsRats, Sprague-DawleyTandem Mass SpectrometryTissue DistributionAnti-Bacterial AgentsClarithromycinClofaziminePyridinessudapyridineclarithromycinclofaziminedrug distributionMycobacterium abscessusWX-081
Identifiers
PMID41744498
PMCPMC13055377
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390